SCHEMBL15537792

SCHEMBL15537792

O=C(NCCCCCc1ccc(F)cc1)n1ccc(=O)[nH]c1=O

nearest known ligand 0.66

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ASAH1 Q13510 4/20 0.49
NAMPT P43490 1/20 0.47
LMNA P02545 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPK3 P27361 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
SQOR Q9Y6N5 1/20 0.46
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15598464 0.88 ASAH1 (0.48) ASAH1
SCHEMBL15538910 0.88 ASAH1 (0.54) ASAH1NAMPT
SCHEMBL15537994 0.86 ASAH1 (0.55) ASAH1NAMPT
SCHEMBL7784441 0.80 ASAH1 (0.61) ASAH1LMNACYP3A4CYP2D6MAPK3
SCHEMBL11668643 0.74 ASAH1 (0.46) ASAH1LMNACYP3A4CYP2D6MAPK3
SCHEMBL15539115 0.71 NAMPT (0.44) NAMPT
SCHEMBL11406796 0.71 ASAH1 (0.67) ASAH1LMNACYP3A4CYP2D6MAPK3
SCHEMBL7058609 0.70 ALDH1A1 (0.43) LMNA
SCHEMBL10937237 0.70 NAMPT (0.59) ASAH1NAMPTSMN1; SMN2KMT2A
SCHEMBL7013073 0.68 TRPV1 (0.53) NAMPTLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2875006-A1 ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS Fondazione Istituto Italiano Di Tecnologia (IT) 2015-05-27 EP claimed
WO-2013178576-A1 ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2013-12-05 WO claimed
EP-2875006-B1 ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2018-12-26 EP disclosed
US-9428465-B2 Acid ceramidase inhibitors and their use as medicaments FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) 2016-08-30 US disclosed
US-9428465-B2 Acid ceramidase inhibitors and their use as medicaments FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) 2016-08-30 US disclosed
EP-2875006-A1 ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS Fondazione Istituto Italiano Di Tecnologia (IT) 2015-05-27 EP disclosed
US-20150111892-A1 ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-04-23 US disclosed
WO-2013178576-A1 ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2013-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111892-A1 ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS ASAH1, ASAH2, ACER2 ASAH1 1/4885NAMPT 179/4885LMNA 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.